StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.78MP/E –Yield –

RedHill Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$7.94M. The highest annual figure on record is -$6.48M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.94M–
FY2024Dec 31, 2024-$6.48M–
FY2023Dec 31, 2023-$9.55M–
FY2022Dec 31, 2022-$42.84M–
FY2021Dec 31, 2021-$81.14M–
FY2020Dec 31, 2020-$63.68M–
FY2019Dec 31, 2019-$43.20M–
FY2018Dec 31, 2018-$39.33M–
FY2017Dec 31, 2017-$51.97M–
FY2016Dec 31, 2016-$30.54M–
FY2015Dec 31, 2015-$22.00M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2022Jun 30, 2022-$9.16M–
Q2 FY2021Jun 30, 2021-$24.89M–
Q2 FY2020Jun 30, 2020-$12.50M–
Q2 FY2019Jun 30, 2019-$12.38M–
Q2 FY2018Jun 30, 2018-$9.56M–
Q2 FY2017Jun 30, 2017-$13.54M–

More RedHill Biopharma figures

See a number that looks wrong?